

**"2019 WAS** AN IMPORTANT YEAR **AS WE TOOK DECISIVE ACTIONS TO REFOCUS** THE PORTFOLIO AND **EMBARK ON** A NEW STRATEGY TO **DRIVE INNOVATION** AND GROWTH."

## PAUL HUDSON

CEO OF SANOFI



2019\*



€5.99 +6.8% (+9.5%) BUSINESS EPS

**SALES BY GLOBAL BUSINESS UNIT** 



€9,195M

Sanofi Genzyme (Speciality Care)







€7,437 M China & Emerging Markets



## **SALES BY GEOGRAPHY**

- **1** U.S **€12,756M**
- 3 LATIN AMERICA €2,734M
- ASIA **€4,393M**
- 6 AFRICA & MIDDLE EAST €2,307M

REST OF THE WORLD\*\* €3,604M 



## R&D **HIGHLIGHTS**

projects in development,

including new molecular entities & additional indications

FOR FURTHER INFORMATION ON FULL YEAR 2019 RESULTS, AND DEFINITIONS OF FINANCIAL INDICATORS,

> ON FEBRUARY 6, 2020 AT: HTTPS://WWW.SANOFI.COM/INVESTORS/

PLEASE REFER TO THE PRESS RELEASE ISSUED

SANOFI.COM





SANOFI.US



